Results 41 to 50 of about 25,343 (258)

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

Neurobiology of Disease, 2010
L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for antidyskinetic therapies.
Daniella Rylander, Hanna Iderberg, Qin Li, Andrzej Dekundy, Jinlan Zhang, Hao Li, Ren Baishen, Wojciech Danysz, Erwan Bezard, M. Angela Cenci   +9 more
doaj   +1 more source

Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)

Frontiers in Neuroscience, 2021
L-DOPA is the criterion standard of treatment for Parkinson disease. Although it alleviates some of the Parkinsonian symptoms, long-term treatment induces L-DOPA–induced dyskinesia (LID).
Kai Yang, Xinyue Zhao, Changcai Wang, Cheng Zeng, Yan Luo, Taolei Sun, Taolei Sun   +6 more
doaj   +1 more source

D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]

, 2005
Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D., Barghshoon, Sami, Chen, Ching-Kang, Cheyette, Benjamin N. R., Ebert, Jana, Kovoor, Abraham, Lester, Henry A., Schwarz, Johannes, Schwarz, Sigrid, Seyffarth, Petra, Simon, Melvin I.   +10 more
core  

Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks. [PDF]

, 2005
In this study, we quantify the severity of drug-induced dyskinesias in the arms of Parkinson's disease (PD) patients using digitised spiral-drawing tasks.
Bain, PG, Carroll, CB, Liu, X, Wang, S-Y, Zajicek, J   +4 more
core   +3 more sources

Targeting Microglial CD49a Inhibits Neuroinflammation and Demonstrates Therapeutic Potential for Parkinson's Disease

Advanced Science, EarlyView.
This study shows that integrin receptor CD49a (Itga1 gene) is significantly upregulated in hyperactivated microglia and microglia‐specific knockdown of Itga1 rescues neuroinflammation and neurodegeneration in a chronic Parkinson's disease (PD) model by targeting PGAM5‐mediated mitochondrial dysfunction and NLRP3 activation. Targeted inhibition of CD49a
Huanpeng Lu, Yunmin Zhu, Xi Wang, Zelin Wu, Zijian Xu, Rongqing Chen, Yanwu Guo   +6 more
wiley   +1 more source

Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials [PDF]

, 2015
Metabotropic glutamate (mGlu) receptors are G protein-coupled receptors expressed primarily on neurons and glial cells modulating the effects of glutamatergic neurotransmission.
Arnau de Bolós, Josep M., Carbonell Bardera, Lourdes, Ciruela Alférez, Francisco, Cuffí i Chéliz, Maria Laura, Fernández Dueñas, Víctor, García Negredo, Gloria, Quijada Manuitt, M. Angeles, Simón, C. P., Sánchez González, S., Vallano Ferraz, Antonio   +9 more
core   +2 more sources

Monoaminylation in Human Health and Disease: State of the Field, Challenges, and Emerging Directions

Advanced Science, EarlyView.
This review delineates monoaminylation—serotonylation, dopaminylation, and histaminylation—as key post‐translational modifications beyond receptor signaling. It details their catalytic mechanisms, roles in gene expression and protein function, and implications in health and disease, aiming to bridge mechanistic insights with therapeutic potential ...
Yiqi Zhao, Hongli Zhang, Yating Yang, Wei‐Dong Chen, Yan‐Dong Wang   +4 more
wiley   +1 more source

Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia [PDF]

, 2017
Background: Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in > 20% of adults taking antipsychotic medication (first-generation antipsychotics for
Adamd, Adler, Adler, Adler, Adler, Adler, Ajimsha, Akhtar, Alabed, American Psychiatric Association, American Psychiatric Association, American Psychiatric Association Task Force on Tardive Dyskinesia, Ananth, Anon, Armitage, Bai, Bai, Bai, Bai, Bai, Bakker, Bakker, Ballesteros, Barnes, Bhoopathi, Bobruff, Bockenheimer, Borenstein, Bradburn, Bratti, Bridler, Bucci, Bucher, Burner, Buruma, Cadet, Cai, Caligiuri, Caroff, Caroff, Caroff, Casey, Castro, Chaimani, Chaimani, Chan, Chen, Chinese Medical Association and Nanjing Medical University, Chouinard, Chouinard, Chouinard, Chouinard, Chouinard, Chouinard, Cipriani, Clarke, Cloud, Cookson, Csernansky, Csernansky, Dabiri, Damier, de Montigny, DerSimonian, Dorevitch, Dorevitch, Edson, Egan, El-Sayeh, Elbourne, Elkashef, Elkins, Elmsley, Emsley, Emsley, Emsley, Emsley, Essali, Feltner, Ferreira, Fisk, Fleiss, Franklin, Garcia, Gardos, Gardos, Gelenberg, George, Gerlach, Gerlach, Glazer, Glazer, Glazer, Glazer, Goff, Greil, Gunne, Guyatt, Guyatt, Hajioff, Haleem, Hardoy, Hebenstreit, Hempel, Higgins, Higgins, Higgins, Higgins, Higgins, Higgins, Huang, Huang, Huang, Jackson, Jackson, Jackson, Jackson, Jahanian, Jansen, Jeste, Jeste, Kajero, Kane, Kane, Kar-Ahmadi, Karniol, Kazamatsuri, Kazamatsuri, Killoran, Kocher, Kojima, Kojima, Koshino, Koshino, Koshino, Kuss, Lam, Langan, Lerner, Libov, Lieberman, Lima, Lingjaerde, Linnoila, Lohr, Lohr, Loonen, Lu, Lublin, MacKay, Maher, Marshall, Martins, Matsunaga, McGrath, Meco, Mei, Mestre, Miller, Miller, Miller, Miller, Mosnik, Mosnik, Mouret, Mustafa, Nair, Nair, National Center for Health Statistics, National Institute for Health and Care Excellence, NCT00114595, NCT00175955, NCT00190008, NCT00291213, NCT00621998, NCT01733121, Ogunmefun, Ojima, Overall, Pappa, Pappa, Pappa, Peselow, Pocock, Pouclet-Courtemanche, Queiroz, R Development Core Team, Rana, Rastogi, Raudenbush, Reynolds, Rhodes, Richardson, Roos, Rosenheck, Rotrosen, Rust, Rücker, Rücker, Rücker, Rücker, Sajjad, Salanti, Salanti, Schmidt, Schooler, Schwartz, Schwartz, Shamir, Shamir, Shi, Simpson, Simpson, Soares, Soares, Soares, Soares-Weiser, Soares-Weiser, Soares-Weiser, Soares-Weiser, Soni, Stewart, Stewart, Sutton, Sweeting, Tammenmaa, Tamminga, Tan, Tarsy, Tarsy, Taylor, Thaker, Tracy, Turner, van Harten, Viechtbauer, Wahbeh, Warren, Weber, White, White, Woerner, Wolkin, Woods, Woods, World Health Organization, Xiang, Yagi, Yagi, Yang, Yassa, Yassa, Yin, Zeng, Zeng, Zeng, Zeng, Zhang, Zhang   +258 more
core   +3 more sources

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

Advanced Science, EarlyView.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély, István Narozsny, Levente Szarka, Daniel V. Veres, Peter Csermely, Dávid Keresztes   +5 more
wiley   +1 more source

Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double‐Blind Primary Endpoint

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objective Published reports on directional deep brain stimulation (DBS) have been limited to small, single‐center investigations. Therapeutic window (TW) is used to describe the range of stimulation amplitudes achieving symptom relief without side effects.
Alfons Schnitzler, Pablo Mir, Matthew A. Brodsky, Leonard Verhagen, Sergiu Groppa, Ramiro Alvarez, Andrew Evans, Marta Blazquez, Sean Nagel, Julie G. Pilitsis, Monika Pötter‐Nerger, Winona Tse, Leonardo Almeida, Nestor Tomycz, Joohi Jimenez‐Shahed, Witold Libionka, Fatima Carrillo, Christian J. Hartmann, Stefan Jun Groiss, Martin Glaser, Florence Defresne, Edward Karst, Binith Cheeran, Jan Vesper, for the PROGRESS Study Investigators   +24 more
wiley   +1 more source